Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Docetaxel, Cisplatin and Fluorouracil (TPF) in Palliative Treatment of Squamous Cell Carcinoma of the Head and Neck
2006-005816-29Phase 2Terminated
- Sponsor
- The Royal Wolverhampton NHS Trust
- Start
- Sep 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by The Royal Wolverhampton NHS Trust. Primary endpoints: Objective response rate (CR + PR) and Tolerability of TPF regimen. Started Sep 2009; status: terminated.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-005816-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005816-29.